When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ORMP - Oramed reaches 50% enrollment in late-stage oral insulin study
Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals (ORMP) has enrolled and randomized over 50% of the 675 patients planned for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes ((T2D)).Efficacy data for ORA-D-013-1 will become available after all patients have completed the first 6-month treatment period, the company said.The company said that it anticipates to announce topline results in 2022.